Suven Life Sciences Ratios

Suven Life Sciences Ltd Ratios

The Suven Life Sciences Ltd Ratios page provides a complete fundamental analysis of Suven Life Sciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Suven Life Sciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Suven Life Sciences Ltd (NSE: SUVEN, BSE: 530239) is currently trading at ₹210.18, with a market capitalization of ₹51.66B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Suven Life Sciences Ltd remains a key stock for fundamental analysis using Suven Life Sciences Ltd Ratios.

Suven Life Sciences Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Suven Life Sciences Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Suven Life Sciences Ltd Ratios.

Historically, the Suven Life Sciences Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Suven Life Sciences Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Suven Life Sciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 22.48.

Historical P/B trend:

• 2024: 22.48
• 2023: 8.05
• 2022: 2.82
• 2021: 14.02

Suven Life Sciences Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Suven Life Sciences Ltd P/S ratio currently stands at 371.55, an important part of Suven Life Sciences Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 371.55
• 2023: 185.94
• 2022: 63.83
• 2021: 99.83

The rising Suven Life Sciences Ltd P/S ratio indicates improved revenue valuation by investors.

Suven Life Sciences Ltd Price to Cash Flow Ratio (P/CF)

The Suven Life Sciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Suven Life Sciences Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The declining Suven Life Sciences Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Suven Life Sciences Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Suven Life Sciences Ltd EV currently stands at ₹24.13B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 24.13B
• 2023: 19.35B
• 2022: 6.35B
• 2021: 11.35B

Suven Life Sciences Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Suven Life Sciences Ltd EV/EBITDA ratio is currently 0, a key metric in Suven Life Sciences Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Stable Suven Life Sciences Ltd EV/EBITDA indicates balanced valuation.

Suven Life Sciences Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Suven Life Sciences Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0.03

Suven Life Sciences Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Suven Life Sciences Ltd ROE currently stands at -84.60%, showing profitability and capital efficiency.

Historical ROE:

• 2024: -84.60
• 2023: -32.56
• 2022: -50.17
• 2021: -119.51

Declining ROE indicates pressure on profitability.

Suven Life Sciences Ltd Ratios Analysis Summary

The Suven Life Sciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Suven Life Sciences Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Suven Life Sciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.